

PF-PTD-117

# **Digoxin**



## **Synonyms**

## **Clinical Indication**

#### Lanoxin

Digoxin is a cardiac glycoside used in the treatment of congestive heart failure and some types of cardiac arrhythmias.

Given the relatively narrow therapeutic window of digoxin, with substantial overlap between so-called therapeutic and toxic levels, patients taking digoxin require monitoring of the serum digoxin concentration, with the "optimal" level varying with the clinical setting. Monitoring the serum digoxin level is particularly important in persons with chronic renal dysfunction or rapidly changing renal function, as significantly decreased renal function can lead to accumulation of digoxin and its metabolites and predispose to digoxin toxicity. Additionally, patients with electrolyte disturbances, particularly hypokalaemia and hypomagnesemia, which may be related to diuretic therapy or other medications, are at increased risk for digoxin-associated arrhythmias and should undergo monitoring of the serum digoxin level until serum potassium level and magnesium concentration return to the normal range.

Toxicity symptoms include nausea, vomiting, visual disturbances (especially colour vision) bradycardia, sweating, convulsions and coma.

An information sheet is available from National Poisons Service (Toxbase).

## Part of Profile / See Also

Request Form

Availability / Frequency of

**Analysis** 

**Turnaround Time** 

**Patient Preparation** 

**Sample Requirements** 

**Specimen Type** 

Volume

**Acceptable Containers** 

Combined Pathology manual Blood form or ICE request.

Please state time after last dose on request form.

On request during routine hours. Laboratory must be contacted regarding urgent requests.

Same day.

Blood samples must be obtained at least 6 hours, but optimally 12 hours, after administration of digoxin to ensure completion of distribution from the blood to the tissues. In patients with advanced kidney disease or who are on haemodialysis, the digoxin level should be checked at least 12 to 24 hours after the prior dose. Serum digoxin concentrations measured prior to these times may be falsely elevated.



2 ml



Yellow top (SST) tube

Plain serum samples may also be used

0.8 - 2.0 μg/L. Target range in heart failure is 0.5 - 1.0 μg/L

Reference: Pathology Harmony Group, Clinical Biochemistry Outcomes, January 2011 (www. pathologyharmony.co.uk)

**Reference Range & Units** 



PF-PTD-117

## Half Life 36-48 hours

Beckman kit insert

**Interferences** 

Digoxin Immune Fab (such as digibind), an antidote for digoxin overdose will interfere with the digoxin assay until the Fab fragment is cleared from the body. Serum digoxin concentration should be determined before administration where possible.

**Interpretation & Clinical** 

**Decision Value (if applicable)** 

A wide range of factors alter clinical response, most importantly hypokalaemia which is associated with enhanced response and may produce digoxin toxicity within the target ranges. Hypercalcaemia, hypomagnesaemia and hypothyroidism are also associated with increased tissue sensitivity.

References

\_\_\_\_

**Test code** 

DIG

**Lab Handling** 

Analysed from primary tube and stored at 4°C Serum stable for 90 days at 2-8°C. Serum stable for 2 weeks at 15-25°C.